Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax
Erstveröffentlichung
2020
Wissenschaftlicher Artikel
Published in
Blood ; 135 (2020), 26. - S. 2402-2412. - ISSN 0006-4971. - eISSN 1528-0020
Link to publication
https://dx.doi.org/10.1182/blood.2019004492Institutions
UKU. Klinik für Innere Medizin IIIDFG Project THU
SFB 1074 / Experimentelle Modelle und klinische Translation bei Leukämien / DFG / 217328187
Subject headings
[Free subject headings]: VenG was superior to GClb across different genetic subgroups | but del(17p) and mutated TP53 remain as adverse prognostic markers | Unmutated IGHV is a predictive factor for particular benefit from venetoclax and obinutuzumab | CHRONIC LYMPHOCYTIC-LEUKEMIA | INDEPENDENT PREDICTOR | CLINICAL IMPACT | MUTATIONS | SURVIVAL | NOTCH1 | PROGRESSION | IBRUTINIB | SF3B1 | BIRC3[DDC subject group]: DDC 610 / Medicine & health